Champions Oncology Announces Research Collaboration with The Addario Lung Cancer Medical Institute to Develop Unique Cohort of Patient-Derived Xenograft (PDX) Models
(World News Science)

Champions Oncology Announces Research Collaboration with The Addario Lung Cancer Medical Institute to Develop Unique Cohort of Patient-Derived Xenograft (PDX) Models HACKENSACK, N.J., August 18, 2017 /PRNewswire/ - Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a collaboration with The Addario Lung Cancer Medical Institute `ALCMI` to develop a novel cohort of PDX models in patients with ROS1 gene rearrangement. These models will further expand Champions` TumorGraft bank offerings in non-small cell lung cancer for translational...